NCT01295736已完成3 期
Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study
University Hospital, Lille48 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2010年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 84
- 试验地点
- 48
- 主要终点
- time to healing of ischemic digital ulcers (DUs) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days
研究概览
简要总结
Digital ulcers (DUs) are an expression of the microangiopathy in patients with scleroderma (SSc). DUs lead to pain and impaired hand use. DUs remain a severe complication for many patients and effective therapy remains elusive. In the present study, the investigators propose to evaluate the efficacy of Sildenafil in DUs healing in a randomized double blind control study in SSc patients.
详细描述
This is a multicenter, prospective, longitudinal, randomized, comparative, double-blind, 2-parallel-arm, placebo-controlled study aimed to evaluate the efficacy of sildenafil 20 mg TID study on time to healing of DUs in SSc patients with ischaemic DUs.
Approximately 120 patients aged from 18 years and above will be allocated to receive either placebo or sildenafil 20mg TID during 90 days. All potential subjects will present with ischaemic digital ulcers complicating scleroderma. An eligible digital ulcer must be beyond the proximal interphalangeal joint, on finger surface (included periungual ulcers), of ischemic origin according to the physician, and not over subcutaneous calcifications or bone relief.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with systemic sclerosis (ScS) according to the classification criteria of the American College of Rheumatology or of "LeRoy" and "Medsger".
- •ScS patient with at least one ongoing ischaemic hand digital ulcer at baseline (see below the eligibility conditions of a digital ulcer).
- •Patient must have provided written informed consent prior to enrolment. Patient agrees to come to the follow up visits inside the protocol specified range.
- •Relative to each DU: DU must be beyond the proximal interphalangeal joint, on finger surface, of ischemic origin according to the physician, and not over subcutaneous calcifications or bone relief.
排除标准
- •PAH requiring PDE5 inhibitors or prostacyclin history of stroke, myocardial infarction or life threatening arrhythmia within the last 6 months
- •severe cardiac failure (NYHA IV) or unstable angina within the last 6 months.
- •hereditary degenerative retinal disorders non-arteritic anterior ischemic optic neuropathy or untreated proliferative diabetic retinopathy
- •uncontrolled diabetes mellitus
- •Patient with known severe lung obstructive disease (FEV1<70% on last available pulmonary function tests).
- •severe hepatic impairment
- •Patient with known impairment of renal function (serum creatinine > 2.5 ULN).
- •Patient with severe malabsorption or any severe organ failure (e.g., lung, kidney) or any life-threatening condition.
- •Patient who has had surgical sympathectomy performed in the previous 12 months.
- •Patient with a history of upper extremity deep vein thrombosis or lymphedema within the previous 3 months.
- •Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months.
- •Patient having received a treatment with sildenafil for digital ulcers or pulmonary arterial hypertension within 3 months prior to inclusion.
- •Patient having received a treatment with parenteral prostanoids (prostaglandin E, epoprostenol, treprostinil sodium or other prostacyclin analogs) within 3 months prior to inclusion.
- •Patient having received a treatment with inhaled or oral prostanoids one month prior to inclusion.
- •Patient with previous intolerance or allergy to PDE5 inhibitors or a history of multiple clinically significant allergies.
- •Pregnant or lactating female.
- •Patient with uncontrolled tachyarrhythmias or bradyarrhythmias, or placement of pacemaker or implantable defibrillator within 60 days prior to randomization.
- •Patient with hemodynamic instability or systolic arterial pressure less than 90 mmHg and/or symptomatic orthostatic hypotension.
- •Patient receiving all forms of prostacyclin or nitrates or nitric oxide donors in any form including Nicorandil.
- •Patient receiving potent inhibitors of CYP3A4 such as ketoconazole, itraconazole, ritonavir.
- •Patient with any condition that prevents compliance with the protocol or adhering to therapy.
- •Patient who has donated blood during the previous month or intends to donate blood or blood products during the study or for one month following completion of the study.
- •Patient under guardianship (including curators) or deprived of liberty.
- •Patient presenting with an anatomic malformation of penis (such as an angulation, sclerosis of erectile tissue or "Lapeyronie's disease").
- •Patient presenting with a disease which predisposes to priapism (such as sickle-cell disease, myeloma or leukemia).
- •Patient presenting with at least one digital ulcer meeting the exclusion criteria (see below).
- •Relative to each DU:
- •Digital ulcer due to conditions other than scleroderma.
- •Non ischaemic digital ulcer.
- •Infected digital ulcer requiring systemic antibiotherapy.
- •Digital ulcer requiring urgent surgery.
研究组 & 干预措施
Sugar pill
Placebo Comparator
Placebo pills TID during 90 days
干预措施: placebo (Drug)
Actif arm
Active Comparator
Sildenafil 20mg TID during 90 days
干预措施: Sildenafil (Drug)
结局指标
主要结局
time to healing of ischemic digital ulcers (DUs) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days
时间窗: 90 days
次要结局
- To evaluate the change in the number of ischaemic DUs between baseline and day 90.(90 days)
- To evaluate the proportion of patients with complicated DUs (infection, gangrene, amputation, DU requiring IV prostanoids) over the 90 days period of treatment.(90 days)
- To evaluate the time to healing of ischemic DUs (2 mm at entry and > 1 month and <3 months old) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days.(90 days)
- To evaluate the proportion of patients with complete healing of all DUs (baseline DUs and new DUs) at day 90.(90 days)
- To evaluate the evolution of the severity of Raynaud's phenomenon between baseline and day 90.(90 days)
- To evaluate the proportion of patients with complete healing of all DUs present at baseline at day 90.(90 days)
- To evaluate the change between baseline and day 90 in hand function and pain.(90 days)
- To evaluate the proportion of patients who do not develop any new DU after 28 days of treatment with the study drug up to day 90.(90 days)
研究者
研究点 (48)
Loading locations...
相似试验
已完成
2 期
Sildenafil for Treatment of Digital Ulcers in Patients With Systemic SclerosisActive Digital UlcersNCT00624273Charite University, Berlin, Germany17
招募中
3 期
Effect of sildenafil on the healing of digital ulcer in Thai systemic sclerosisSystemic sclerosisEfficacyDigital ulcerSildenafilQuality of lifeSclerodermaTCTR20170426001Facultyof Medicine, Khon Kaen University30
已完成
2 期
Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital UlcersDigital Ulcer of SclerodermaNCT02801305Mohammad Ali Nazarinia90
招募中
不适用
Study of Diosmin for the Treatment of Digital Ulcers in Systemic SclerosisScleroderma, SystemicDigital UlcerNCT06256575Primus Pharmaceuticals45
已完成
3 期
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic SclerosisScleroderma, SystemicScleroderma, DiffuseScleroderma, LimitedRaynaud PhenomenonNCT01347008Federal University of São Paulo41